Page last updated: 2024-08-21

thiazoles and siponimod

thiazoles has been researched along with siponimod in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	3 (75.00)	24.3611
2020's	1 (25.00)	2.80

Authors

Authors	Studies
Dolgin, E	1
Chaudhry, BZ; Cohen, JA; Conway, DS	1
Bar-Or, A; Filippi, M; Piehl, F; Preziosa, P; Rocca, MA; Solari, A; Vukusic, S	1
Cohen, JA; McGinley, MP	1

Reviews

3 review(s) available for thiazoles and siponimod

Article	Year
Sphingosine 1-Phosphate Receptor Modulators for the Treatment of Multiple Sclerosis. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2017, Volume: 14, Issue:4 Topics: Animals; Azetidines; Benzyl Compounds; Clinical Trials as Topic; Fingolimod Hydrochloride; Humans; Immunologic Factors; Indans; Indoles; Multiple Sclerosis; Naphthalenes; Oxadiazoles; Propanolamines; Receptors, Lysosphingolipid; Thiazoles; Treatment Outcome	2017
Multiple sclerosis. Nature reviews. Disease primers, 2018, 11-08, Volume: 4, Issue:1 Topics: Azetidines; Benzyl Compounds; Demyelinating Diseases; Humans; Indans; Magnetic Resonance Imaging; Multiple Sclerosis; Oxadiazoles; Risk Factors; Thiazoles; Tomography, X-Ray Computed	2018
Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions. Lancet (London, England), 2021, 09-25, Volume: 398, Issue:10306 Topics: Animals; Azetidines; Benzyl Compounds; Clinical Trials as Topic; Fingolimod Hydrochloride; Humans; Immune System Diseases; Indans; Multiple Sclerosis; Nervous System Diseases; Oxadiazoles; Signal Transduction; Sphingosine 1 Phosphate Receptor Modulators; Sphingosine-1-Phosphate Receptors; Thiazoles	2021

Other Studies

1 other study(ies) available for thiazoles and siponimod

Article	Year
Therapies: Progressive steps. Nature, 2016, 11-30, Volume: 540, Issue:7631 Topics: Animals; Antibodies, Monoclonal, Humanized; Antigens, CD20; Azetidines; B-Lymphocytes; Benzamides; Benzyl Compounds; Blood-Brain Barrier; Clinical Trials as Topic; Disease Progression; Dogs; Drug Approval; Fingolimod Hydrochloride; Hope; Humans; Male; Mice; Multiple Sclerosis, Chronic Progressive; Neuroprotective Agents; Piperidines; Precision Medicine; Pyridines; Rituximab; Thiazoles; Ubiquinone; United States; United States Food and Drug Administration	2016

Article

Year

Therapies: Progressive steps.

Nature, 2016, 11-30, Volume: 540, Issue:7631

Topics: Animals; Antibodies, Monoclonal, Humanized; Antigens, CD20; Azetidines; B-Lymphocytes; Benzamides; Benzyl Compounds; Blood-Brain Barrier; Clinical Trials as Topic; Disease Progression; Dogs; Drug Approval; Fingolimod Hydrochloride; Hope; Humans; Male; Mice; Multiple Sclerosis, Chronic Progressive; Neuroprotective Agents; Piperidines; Precision Medicine; Pyridines; Rituximab; Thiazoles; Ubiquinone; United States; United States Food and Drug Administration

2016